Buying ProPhase Labs stock in 2026: price, results and risks

Are you looking for information to buy ProPhase Labs stock (ProPhase Labs, PRPH)? This file must first be read as a warning: the company moved from the Nasdaq to over-the-counter (OTC) quotation, its capitalisation has collapsed and its losses pile up. Here are the real activity, the latest accounts and the risks before any decision.

ProPhase Labs stock profile

CompanyProPhase Labs, Inc. (formerly The Quigley Corporation)
MarketOTC (American over-the-counter market) — ex-Nasdaq, checked on 10/11/2026
TickerPRPH
SectorDiagnostics & research — food supplements, diagnostic tests, genomics
Quotation currencyUS dollar (USD)
Fiscal year end31 December
EmployeesAbout 19 staff
PEA eligibilityNo (American issuer)

ProPhase Labs presentation: activity and markets

From food supplements to diagnostics

ProPhase Labs develops and markets drugs, food supplements and compounds in the United States, through two segments: diagnostic services and consumer products. The historical range includes the TK supplements like Legendz XL and Triple Edge XL, inherited from its past as a maker of popular health products.

The oesophageal diagnostics bet

The company’s industrial bet rests on BE-Smart Esophageal, a screening test designed to detect oesophageal cancer early, as well as genome-sequencing technologies. These projects remain at the commercial-development stage: they consume cash and have not yet demonstrated large-scale profitability.

A financial trajectory in a spiral

After the Covid-test boom, which temporarily boosted sales, the activity contracted year after year. The repeated losses, the successive financial operations and the collapse of the capitalisation make the stock a textbook case of a distressed micro-cap; the transfer from the Nasdaq to the OTC is the most visible symptom of this trajectory.

ProPhase Labs results and financial data

Consolidated accounts of the last three fiscal years ended 31 December:

IndicatorFY 2023FY 2024FY 2025One-year change
Revenue$34.98m$6.77m$4.35m-35.8%
Net income-$16.78m-$53.36m-$14.74mreduced loss

Amounts in millions of dollars. Source: S&P Global Market Intelligence via StockAnalysis, consolidated accounts; data consulted on 10/11/2026.

The reading is brutal: 2025 revenue has fallen back to about one-eighth of its 2023 level, and every fiscal year ends with losses in the tens of millions of dollars. The 2025 loss is however more contained than in 2024, after restructuring and asset-disposal operations led by management.

ProPhase Labs stock dividend

ProPhase Labs pays no dividend and has paid none in recent fiscal years. The priority is financial survival: financing the diagnostic programmes, absorbing the losses and preserving cash.

On such a profile, performance can only come from a speculative price rebound or a corporate transaction. It is a near-certain-loss bet if the programmes fail; no yield cushions the wait.

Should You Buy ProPhase Labs Stock in 2026?

Strengths:

  • An original screening product (BE-Smart Esophageal) on a real medical need.
  • A 2025 loss reduced versus 2024, a sign of ongoing restructuring.
  • An already-collapsed valuation: a medical or industrial success would have maximum mechanical leverage.

Points to watch:

  • OTC quotation: very low liquidity, wide spreads, limited access at French brokers.
  • A capitalisation in the hundreds of thousands of dollars only: dilution and disappearance possible.
  • Accumulated losses over several fiscal years and continuously contracting revenue.
  • Delisting risk: a delisting or bankruptcy would lose the entire stake.

In all honesty: this is not an investment file to recommend, it is a very-high-risk bet, reserved — at most — for a derisory fraction of the portfolio of an investor who understands they can lose everything. If you are looking for American small caps, first compare stronger files among the best stocks on the market.

Fundamental and technical analysis of PRPH stock

Fundamental analysis

The only criterion that counts is cash relative to the pace of losses: how many more quarters can the company finance its programmes? Then come possible partnerships or licences on the oesophageal test. Without outside financing or monetisation, the accounting trajectory is mathematically unsustainable.

Technical analysis

On the OTC, technical analysis keeps little value: volumes are too low for reliable trends to emerge, and a single order can move the price by tens of percent. The order book is thin, bid-ask spreads wide: quick exits at a good price are never guaranteed.

How to buy ProPhase Labs stock?

Buying PRPH is possible but restrictive: over-the-counter quotation is not offered by all European brokers.

  1. Check OTC access with your broker: our comparison of brokers indicates which securities accounts give access to American over-the-counter stocks.
  2. Open an ordinary securities account — the PEA does not accept American issuers — and fill in the W-8BEN form.
  3. Place a limit order on PRPH, in very progressive amounts, never at market: quotation spreads are wide and execution uncertain.

Hours and taxation

The American OTC market trades during American session hours, generally 3:30 pm to 10:00 pm Paris time; the rules of the game differ significantly from the regulated markets described in our guide to the stock market. Capital gains remain taxed in France at the 30% single flat levy, on an ordinary securities account.

Frequently asked questions about ProPhase Labs stock

Is ProPhase Labs still listed on the Nasdaq?

No. The company now trades on the American OTC market under the symbol PRPH, after leaving the Nasdaq. Always check the live quotation with your broker before any order.

What is ProPhase Labs worth today?

Very little: the capitalisation counts in the hundreds of thousands of dollars, for revenue of $4.35 million in 2025 and recurring losses. It is a stock in financial distress.

Does ProPhase pay a dividend?

No. No dividend is paid; all financial resources are absorbed by the losses and the financing of the diagnostic programmes.

Can PRPH go in a PEA?

No. The company is American: the stock is eligible neither for the PEA nor the PEA-PME and is held only in an ordinary securities account.

What is this stock’s main risk?

Total loss of capital: successive dilution, unguaranteed financing and very low OTC liquidity. The price can become negligible without the difficulties being resolved.

Disclaimer: this content is informational and does not constitute investment advice. Investing in the stock market carries a risk of capital loss; past performance is not indicative of future performance.

Tableau originalDiversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

ProPhase Labs: profile and business model

ProPhase Labs is a listed company whose stock is bought through an online broker. Before any decision, verify the updated information — exact sector, capitalisation, listing venue and ticker code — in the issuer’s latest regulated news: these elements change (spin-offs, renamings, index changes).

How to buy ProPhase Labs stock: the complete method

  1. Open a securities account (or a PEA if the stock is eligible) with a regulated broker;
  2. Search for the ProPhase Labs stock on the listing venue indicated by the issuer;
  3. Place a limit order — essential on an illiquid stock: a market order can execute very far from the last displayed price;
  4. Size the position: maximum 2-5% of the portfolio per line, with your written investment thesis (why I buy, when I sell).

For the complete selection method before buying: how to buy stocks and our PEA dossier for eligible stocks.

Sector analysis and positioning

Every stock sits in a sector with its own cycles: technology and healthcare reward growth, finance and energy reward dividends, industry depends on order books. Three questions to place a company in its sector: what is its durable competitive advantage (brand, patent, network, cost)? What market share does it hold and in which direction is it moving? Is the sector in structural growth or decline? A solid company in a declining sector remains a risky investment; an average company in a growing sector can outperform. Always combine this reading with the cycle position: cyclical stocks (automotive, luxury, materials) offer the best opportunities early in the cycle and the worst at the end of it.

Dividends and shareholder policy

A dividend is a cash flow paid to shareholders, decided at the general meeting on the board’s proposal. Three indicators to assess it: the yield (annual dividend / share price); the payout ratio (the share of net profit paid out — beyond 80%, sustainability becomes doubtful); and regularity (a dividend cut almost always signals trouble). Beware of abnormally high yields (>10%): the market usually anticipates an upcoming reduction. To go further: our dividends dossier.

Strengths, risks and points to watch

Strengths to document: market position, recurring cash-flow generation, controlled indebtedness (net debt / EBITDA below 2-3 depending on the sector), quality of management. Risks to monitor: customer or geographic concentration, technological dependence, exposure to exchange rates, ongoing litigation, family governance or a dominant controlling shareholder. The good practice: write the investment thesis in three lines (why I buy, what would validate the thesis, what would invalidate it) and reread it at every earnings release.

Classic mistakes of the retail investor

Behavioural studies consistently document the same costly biases. Anchoring: clinging to your purchase price as a reference (« I’ll sell when I get back to my level ») while the market completely ignores that price. Loss aversion: selling winners too quickly and keeping losers too long — the opposite of rational discipline. Confirmation bias: reading only the analyses that confirm the position already held. Herding: buying what everyone is talking about, often at the worst moment. The antidote comes down to three practices: a written thesis at purchase (reread at every earnings release), selling rules defined before becoming emotional, and an error journal where every failed decision is recorded with its real cause — not the convenient one.

Taxation and wrappers: PEA or securities account (France)

The following applies to investors taxed in France, the site’s home market. Two wrappers exist there for holding stocks. The PEA: a ceiling of €150,000 in payments, eligibility limited to European stocks, but after 5 years of holding, capital gains are exempt from income tax (only the 17.2% social levies remain due); dividends compound tax-free as long as they are not withdrawn. The ordinary securities account: no payment limit, access to all world markets, but taxation on every flow (30% flat tax on capital gains and dividends, or the progressive scale with a holding-period allowance for securities acquired before 2018). For European stocks held long, the PEA wins; for global diversification (United States, Asia), the securities account is the natural choice. UK readers hold equivalents such as the ISA or SIPP; US readers have Roth or traditional brokerage retirement accounts — check the rules of your own jurisdiction before choosing a wrapper.

FAQ

What minimum budget to start investing in stocks?

Most online brokers accept first payments of 50 to 100 €. What matters is not the initial amount but regularity: scheduled monthly payments (DCA) smooth out timing risk.

Should you buy all at once or spread purchases?

Spreading purchases (DCA) reduces the risk of buying at the top; a one-off purchase maximises return if the market then rises. Over long horizons, documented studies show a slight edge for lump-sum buying, but spreading dominates psychologically for a beginner.

How to limit the risk of loss?

Three levers: diversification (at least 15-20 lines or one broad ETF), position sizing (no single line above 5% of the portfolio) and horizon (the longer it is, the more bad-timing risk falls).

Where to follow the price and news of a stock?

Real-time quotes are available on the issuer’s website, broker platforms and financial news feeds; shareholders receive regulated press releases by email after registering with the issuer.

Glossary: the terms to know

  • Market capitalisation: price × number of shares; a company’s « size » on the market.
  • P/E (price earnings ratio): price / earnings per share; how many years of profit you are paying for. Below 15: a cautious market or neglected stocks; above 25: strong growth expectations.
  • Earnings per share (EPS): net profit / number of shares; the basis of the P/E calculation.
  • Dividend yield: annual dividend / price; to compare with the money-market rate and government bonds.
  • Free cash flow: cash generated after investments; the real source of dividends and buybacks.
  • Net debt / EBITDA: indebtedness indicator; beyond 3-4 depending on the sector, room for manoeuvre narrows.
  • Limit order: an order with a maximum buy price (or minimum sell price) set in advance; indispensable protection on illiquid stocks.
  • Spread: the gap between buy and sell prices; on small caps it can cost more than the commission.
  • Risk premium: the extra return demanded for holding a stock rather than a risk-free asset.
  • Volatility: the amplitude of swings; it measures short-term risk, not company quality.
  • Beta: a stock’s sensitivity to the market; beta above 1 = amplifies index moves, below 1 = dampens them.
  • Free float: the share of capital actually tradable on the market; a low float makes the price more volatile.
  • Share buyback: the company repurchases its own shares; a cash-return mechanism that supports earnings per share.
  • Adjusted earnings: profit restated for exceptional items as presented by the company; take it with perspective, the definition varies from one issuer to another.

Informational content, not investment advice. Past performance does not predict future performance; investing in stocks carries a risk of capital loss.

Suivez-nous sur Telegram